Search Results - "Sikes, Carolyn"

Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder by Teuscher, Nathan S, Sikes, Carolyn R, McMahen, Russ, Engelking, Dorothy

“…A methylphenidate (MPH) extended-release orally disintegrating tablet (MPH XR-ODT) formulation was recently approved for attention-deficit/hyperactivity…”
Get full text

An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children by Marraffino, Andrea, Sikes, Carolyn R, Laage, Thomas, Volosov, Andrew, Hart, Alison, Engelking, Dorothy

“…In the U.S. ∼33% of children with attention-deficit/hyperactivity disorder (ADHD) are diagnosed during their preschool years (<6 years of age). The majority of…”
Get more information

Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a department of veterans affairs setting by FRIEDMAN, Matthew J, MARMAR, Charles R, BAKER, Dewleen G, SIKES, Carolyn R, FARFEL, Gail M

“…To evaluate the efficacy of sertraline in the treatment of posttraumatic stress disorder (PTSD) in a Veterans Affairs (VA) clinic setting involving patients…”
Get full text

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting by Childress, Ann C, Kollins, Scott H, Cutler, Andrew J, Marraffino, Andrea, Sikes, Carolyn R

“…Methylphenidate extended-release orally disintegrating tablets (MPH XR-ODTs) represent a new technology for MPH delivery. ODTs disintegrate in the mouth…”
Get more information

6.46 PHARMACOKINETICS OF A NOVEL EXTENDED-RELEASE ORALLY DISINTEGRATING TABLET AMPHETAMINE FORMULATION UNDER FED AND FASTED CONDITIONS by Mcmahen, Russ L, Stark, Jeffrey G, Engelking, Dorothy, Sikes, Carolyn R., PhD

“…Objectives: The goals of this session are as follows: 1) to describe the technology underlying amphetamine-extended release-orally disintegrating tablets (AMP…”
Get full text

Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder: A Randomized Controlled Trial by Brady, Kathleen, Pearlstein, Teri, Asnis, Gregory M, Baker, Dewleen, Rothbaum, Barbara, Sikes, Carolyn R, Farfel, Gail M

“…CONTEXT Despite the high prevalence, chronicity, and associated comorbidity of posttraumatic stress disorder (PTSD) in the community, few placebo-controlled…”
Get full text

Severe Vascular Events in Migraine Patients by Velentgas, Priscilla, Cole, J. Alexander, Mo, Jingping, Sikes, Carolyn R., Walker, Alexander M.

“…Objective.—To estimate rates of vascular events in relation to dispensing of triptans and ergot alkaloids among migraineurs, and to compare these rates with…”
Get full text

A Phase 4, Open-Label, Single-Dose Pharmacokinetic Study of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet Formulation in Preschool-Aged Children by Sikes, Carolyn

Get full text

Eletriptan in Migraine Patients Reporting Unsatisfactory Response to Rizatriptan by Goldstein, Jerome, Tiseo, Paul T., Albert, Kenneth S., Li, Chunming, Sikes, Carolyn R.

“…Objective.—The objective of this open‐label study was to evaluate the efficacy of switching patients who had a previous unsatisfactory response to rizatriptan…”
Get full text

Comparative Efficacy of Eletriptan 40 mg Versus Sumatriptan 100 mg by Mathew, Ninan T., Schoenen, Jean, Winner, Paul, Muirhead, Nancy, Sikes, Carolyn R.

“…Objective.—To confirm the efficacy advantage of eletriptan 40 mg over sumatriptan 100 mg. Background.—Eletriptan 80 mg has demonstrated significantly greater…”
Get full text

5.10 EFFICACY AND SAFETY OF AN EXTENDED-RELEASE, ORALLY DISINTEGRATING METHYLPHENIDATE TABLET IN CHILDREN 6-12 YEARS OF AGE BASED ON ADHD RATING SCALE-IV SCORE AT BASELINE by Ann Catherine Childress, Kollins, Scott H., Cutler, Andrew J., Marraffino, Andrea, Sikes, Carolyn

Get full text

In Vivo Disintegration Profiles of Encapsulated and Nonencapsulated Sumatriptan: Gamma Scintigraphy in Healthy Volunteers by Wilding, Ian R., Clark, Darren, Wray, Heather, Alderman, Jeff, Muirhead, Nancy, Sikes, Carolyn R.

“…The goal of this exploratory pilot study was to use gamma scintigraphy to evaluate, under physiological conditions, disintegration profiles of encapsulated and…”
Get full text

6.37 Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder by Teuscher, Nathan, Sikes, Carolyn, Mcmahen, Russ, Engelking, Dorothy

Get full text

6.66 A PHASE 4, OPEN-LABEL, SINGLE-DOSE PHARMACOKINETIC STUDY OF A NOVEL METHYLPHENIDATE EXTENDED-RELEASE ORALLY DISINTEGRATING TABLET FORMULATION IN PRESCHOOL-AGED CHILDREN by Sikes, Carolyn, Laage, Thomas, Volosov, Andrew, Hart, Alison, Engelking, Dorothy, Marraffino, Andrea

Get full text

Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study by Sikes, Carolyn, Stark, Jeffrey G., McMahen, Russ, Engelking, Dorothy

“…A new amphetamine extended-release liquid formulation (AMP XR-OS), intended for the treatment of attention-deficit/hyperactivity disorder, has been developed…”
Get full text

Pharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder by Stark, Jeffrey G, Engelking, Dorothy, McMahen, Russ, Sikes, Carolyn

“…A novel formulation for treating attention-deficit/hyperactivity disorder (ADHD) has recently been developed-amphetamine extended-release orally disintegrating…”
Get more information

A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults by Sikes, Carolyn, Stark, Jeffrey G., McMahen, Russ, Engelking, Dorothy

“…Objective: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard…”
Get full text

2.45 A Phase 4, Open-Label, Multicenter, Single-Dose Study of the Pharmacokinetics of a Novel Amphetamine Extended-Release Oral Disintegrating Tablet Formulation (Adzenys XR-ODT™) in Preschool-Aged Children by Riesenberg, Robert A., Marraffino, Andrea, Engelking, Dorothy, Laage, Thomas, Volosov, Andrew, Hart, Alison, Sikes, Carolyn

“…One in 3 US children are diagnosed with ADHD during the preschool years (age <6 years). Despite few FDA-approved ADHD medications, limited pharmacokinetics…”
Get full text

A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder by Childress, Ann, Newcorn, Jeffrey, Stark, Jeffrey G, McMahen, Russ, Tengler, Mark, Sikes, Carolyn

“…To determine the pharmacokinetic (PK) profile of a proprietary formulation of methylphenidate (MPH) in children and adolescents with…”
Get more information

A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults by Newcorn, Jeffrey H., Stark, Jeffrey G., Adcock, Sherilyn, McMahen, Russ, Sikes, Carolyn

“…There is a strong association between attention-deficit/hyperactivity disorder (ADHD) and alcohol abuse, yet no studies have systematically assessed the effect…”
Get full text